{"id":"NCT00073021","sponsor":"Warner Chilcott","briefTitle":"Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis","officialTitle":"A Double-Blind, Randomized, 6-Week, Parallel-Group Design Clinical Trial to Assess Safety and Efficacy of Asacol 4.8 g/Day (800 mg Tablet) Versus Asacol 2.4 g/Day (400 mg Tablet) for the Treatment of Moderately Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2000-09","primaryCompletion":"2003-09","completion":"2003-09","firstPosted":"2003-11-17","resultsPosted":"2011-07-28","lastUpdate":"2015-06-29"},"enrollment":386,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Asacol 800 mg (mesalamine)","otherNames":[]},{"type":"DRUG","name":"Asacol 400 mg (mesalamine)","otherNames":[]}],"arms":[{"label":"Asacol 2.4 g/day","type":"ACTIVE_COMPARATOR"},{"label":"Asacol 4.8 g/day","type":"EXPERIMENTAL"}],"summary":"This study is a prospective clinical study to evaluate the safety and efficacy of two different doses of Asacol for the treatment of moderately active ulcerative colitis. In addition, a new tablet formulation will be evaluated at one of the two doses.","primaryOutcome":{"measure":"Percentage of Treatment Success Patients at Week 6, ITT (Intent to Treat) Population","timeFrame":"6 Weeks","effectByArm":[{"arm":"Asacol 2.4 g/Day","deltaMin":59.2,"sd":null},{"arm":"Asacol 4.8 g/Day","deltaMin":71.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0357"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":57,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":["21385195","21255059"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":139},"commonTop":["Headache","Pain, Abdominal","Infection","Diarrhea","Nausea"]}}